Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADXS-504 |
Synonyms | |
Therapy Description |
ADXS-504 is an attenuated Listeria monocytogenes-based therapy containing a truncated fragment of listeriolysin O (tLLO) linked to 24 tumor-associated antigens, which potentially modulates the tumor microenvironment and reduces metastasis (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS5115). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADXS-504 | ADXS504|ADXS 504 | ADXS-504 is an attenuated Listeria monocytogenes-based therapy containing a truncated fragment of listeriolysin O (tLLO) linked to 24 tumor-associated antigens, which potentially modulates the tumor microenvironment and reduces metastasis (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS5115). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05077098 | Phase I | ADXS-504 | Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer | Recruiting | USA | 0 |